title: [Feasibility study for Intercept platelets].
abstract: During 3 months, platelet concentrates prepared by "Établissement français du sang Pyrénées-Méditerranée" (Blood bank) were treated with the Intercept process (CERUS©). This study primarily aimed to measure the organizational impact of this technology on transfusion chain. The introduction of Intercept did not raise any major difficulties, but required some adaptations upstream from the deployment. Prior information of health care institutions and physician was essential to anticipate the practical changes, including the prescription of platelet concentrates (CMV negative, irradiation). This study allowed to analyze also the transfusion consequences for patients, in the form of observational studies. The patients transfused with platelet concentrates treated with Intercept received more platelet concentrates (+12.9%), less rich in platelets (-12.8%), the cumulated quantity of platelet being stable.
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France. Electronic address: laurent.bardiaux@efs.sante.fr.
authors.forename: L
authors.initials: L
authors.lastname: Bardiaux
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: S
authors.initials: S
authors.lastname: Vauzou
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: B
authors.initials: B
authors.lastname: Olivier
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: D
authors.initials: D
authors.lastname: Mathieu-Daude
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: E
authors.initials: E
authors.lastname: Durand
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: C
authors.initials: C
authors.lastname: Dite
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, avenue de Grande-Bretagne, BP3210, 31027 Toulouse cedex 3, France.
authors.forename: F
authors.initials: F
authors.lastname: Roubinet
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects* / Q000528:radiation effects; D003587:Cytomegalovirus / Q000276:immunology; D004890:Erythema / Q000209:etiology; D017707:Erythrocyte Transfusion; D005240:Feasibility Studies; D005500:Follow-Up Studies; D011564:Furocoumarins / Q000494:pharmacology*; D006801:Humans; D007231:Infant, Newborn; D064887:Observational Studies as Topic; D017319:Photosensitizing Agents / Q000494:pharmacology*; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects / Q000379:methods*; D055656:Prescriptions; D054098:Thrombocytopenia, Neonatal Alloimmune / Q000628:therapy; D014466:Ultraviolet Rays; D038301:Virus Inactivation
chemical_list: D000914:Antibodies, Viral; D011564:Furocoumarins; D017319:Photosensitizing Agents; C118577:amotosalen
keywords: Amotosalen; Concentrés plaquettaires; Intercept; Platelet concentrates; Transfusion